慢性乙型肝炎病毒感染合并代谢相关脂肪性肝病临床研究进展OA北大核心CSTPCD
Clinical research progress of hepatitis B virus infection concurrent with metabolic dysfunction-associated fatty liver disease
乙型肝炎病毒(HBV)感染和代谢相关脂肪性肝病(MAFLD)是全球最常见的慢性肝病.近年来,随着MAFLD发病率的上升,临床上常见慢性HBV感染合并MAFLD患者.尽管目前已经明确MAFLD可导致终末期肝病和多种肝外不良结局,但其与HBV的相互作用及对慢性感染患者的影响尚存在争议.文章评估慢性HBV感染患者合并MAFLD的流行病学特征,并着重探讨合并MAFLD对慢性HBV感染者临床转归的影响及慢性HBV感染合并MAFLD患者的临床管理策略,以期为临床医生提供重要参考.
Hepatitis B virus(HBV)infection and metabolic dysfunction-associated fatty liver disease(MAFLD)are the most common chronic liver diseases worldwide.In recent years,with the increasing incidence of MAFLD,the coexistence of chronic HBV infection and MAFLD has become more common.Although MAFLD can lead to end-stage liver disease and various extrahepatic adverse outcomes,the interaction between MAFLD and HBV and its clinical impact on chronic hepatitis B have not been fully elucidated.Therefore,we evaluated the epidemiological characteristics of chronic HBV infection concurrent with MAFLD,focused on the influence of coexisting MAFLD on the clinical outcome of chronic HBV infection,and the clinical management strategies for patients with chronic HBV infection concurrent with MAFLD.This reviewaims to provide clinical inspirations for clinicians.
马晓艳;耿楠;芮法娟;倪文婧;施军平;李婕
南京大学医学院附属鼓楼医院感染性疾病科,江苏南京 210008杭州师范大学附属医院感染性疾病科,浙江杭州 311121
临床医学
慢性乙型肝炎病毒感染代谢相关脂肪性肝病流行病学预后转归临床管理
chronic hepatitis Bmetabolic dysfunction-associated fatty liver diseaseprevalenceprognosisclinical management
《中国实用内科杂志》 2024 (001)
17-21,32 / 6
国家自然科学基金面上项目(819705457,82170609);山东省自然科学基金重点项目(ZR2020KH006)
评论